Ganaxolone and Diazepam Administered Intravenously Synergistically Block Seizures in Animal Model of Status Epilepticus
November 15, 2016 07:30 ET
|
Marinus Pharmaceuticals, Inc.
Data Presented at Neuroscience 2016 RADNOR, Pa., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of...
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2016 Financial Results
November 03, 2016 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy...
Ganaxolone Phase 1 Data Supports Progressing to Phase 2 in Patients with Status Epilepticus
October 19, 2016 07:30 ET
|
Marinus Pharmaceuticals, Inc.
Data Presented at the 141st Annual Meeting of the American Neurological Association RADNOR, Pa., Oct. 19, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical...
Ganaxolone Reduces Seizures in Females with PCDH19 Pediatric Epilepsy
September 29, 2016 09:00 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy...
Marinus Appoints Seth H.Z. Fischer to its Board of Directors
September 07, 2016 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy...
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2016 Financial Results
August 09, 2016 16:15 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy...
Results from Phase 2 Exploratory Clinical Study Support Continued Development of Ganaxolone in Fragile X Syndrome
June 28, 2016 07:30 ET
|
Marinus Pharmaceuticals, Inc.
Anxiety and Hyperactivity Benefit shown in FXS Children Study Investigator to Participate in Conference Call and Webcast Today at 9:00 a.m. ET RADNOR, Pa., June 28, 2016 (GLOBE NEWSWIRE)...
Marinus Pharmaceuticals to Host Conference Call on Tuesday, June 28
June 27, 2016 16:05 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., June 27, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy...
Marinus Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV
June 22, 2016 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., June 22, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy...
Marinus Pharmaceuticals Announces Top-Line Results from Phase 3 Trial in Adult Focal Onset Seizures
June 13, 2016 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., June 13, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy...